Comparative Effectiveness In Coverage Decisions: Restrictions Added To House Health Reform Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Federally-funded comparative effectiveness research could not be used by the government to "deny or ration care" or as the basis for making cost-driven coverage decisions, under amendments to the House health reform legislation adopted in markup.
You may also be interested in...
Comparative Effectiveness Research On Track To Be Resolved In Conference
Independent versus government-based CER group is one of issues likely to be left to House/Senate negotiators.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.